Abstract: The present invention relates to a process for preparation of erlotinib of Formula I or its pharmaceutically acceptable salt thereof The present invention also relates to process for the preparation of erlotinib trifluoroacetate. The present invention also relates to a novelCrystalline form of erlotinib trifluoroacetate designated as Form E and process for its preparation. The present invention further relates to process for the preparation of erlotinib hydrochloride from erlotinib trifluoroacetate.
NA
| # | Name | Date |
|---|---|---|
| 1 | 8205-DELNP-2011-AbandonedLetter.pdf | 2018-02-02 |
| 1 | 8205-delnp-2011-Form-2.pdf | 2012-04-05 |
| 2 | 8205-delnp-2011-Form-1.pdf | 2012-04-05 |
| 2 | 8205-DELNP-2011-FER.pdf | 2017-07-12 |
| 3 | 8205-delnp-2011-Drawings.pdf | 2012-04-05 |
| 3 | 8205-delnp-2011-Correspondence Others-(18-03-2013).pdf | 2013-03-18 |
| 4 | 8205-delnp-2011-Form-18-(18-03-2013).pdf | 2013-03-18 |
| 4 | 8205-delnp-2011-Description (Complete).pdf | 2012-04-05 |
| 5 | 8205-delnp-2011-Correspondence Others.pdf | 2012-04-05 |
| 5 | Abstarct Jpg.pdf | 2012-06-15 |
| 6 | 8205-delnp-2011-Abstract.pdf | 2012-04-05 |
| 6 | 8205-delnp-2011-Claims.pdf | 2012-04-05 |
| 7 | 8205-delnp-2011-Abstract.pdf | 2012-04-05 |
| 7 | 8205-delnp-2011-Claims.pdf | 2012-04-05 |
| 8 | 8205-delnp-2011-Correspondence Others.pdf | 2012-04-05 |
| 8 | Abstarct Jpg.pdf | 2012-06-15 |
| 9 | 8205-delnp-2011-Description (Complete).pdf | 2012-04-05 |
| 9 | 8205-delnp-2011-Form-18-(18-03-2013).pdf | 2013-03-18 |
| 10 | 8205-delnp-2011-Drawings.pdf | 2012-04-05 |
| 10 | 8205-delnp-2011-Correspondence Others-(18-03-2013).pdf | 2013-03-18 |
| 11 | 8205-delnp-2011-Form-1.pdf | 2012-04-05 |
| 11 | 8205-DELNP-2011-FER.pdf | 2017-07-12 |
| 12 | 8205-delnp-2011-Form-2.pdf | 2012-04-05 |
| 12 | 8205-DELNP-2011-AbandonedLetter.pdf | 2018-02-02 |
| 1 | SEARCHSTRATEGY_30-06-2017.pdf |